Association of sleep quality with lower urinary tract symptoms/benign prostatic hyperplasia among men in China: A cross-sectional study

Yifan Li, Xianghong Zhou, Shi Qiu, Boyu Cai, Sheng Wang, Lei Chen, Dan Hu, Zhongyuan Jiang, Mingda Wang, Xingyu Xiong, Kun Jin, Qiang Wei, Lu Yang and Li Ma

Objective: As the population aged, voiding dysfunction has been steadily rising among males during the past decade. Increasing evidence showed that sleep disorders are associated with an increasing risk of various diseases, but the association between sleep disorders and lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) among Chinese males have not well characterized.

Materials and methods: We conducted a cross-sectional analysis of data from West China Natural Population Cohort Study (WCNPCS) 2019–2021. Sleep quality was assessed by Pittsburgh sleep quality index (PSQI) in Chinese version. LUTS/BPH as a dependent variable of a binary variable, assessed by a self-reported questionnaire. Multivariate logistic regression analysis were performed to evaluate the correlation between sleep disorders and the risk of LUTS/BPH after adjusting for confounding factors.

Results: 11,824 eligible Chinese men participated in this cross-sectional survey. In multivariate logistic regression analysis, after adjusting for confounding variables, global PSQI score (OR: 1.257, 1.119–1.411, p < 0.001) and its six compounds (Subjective sleep quality: OR: 1.376, 1.004–1.886, p = 0.048; Sleep latency: OR: 0.656, 0.557–0.773, p < 0.001; Sleep duration: OR: 1.441, 1.189–1.745, p < 0.001; Habitual sleep efficiency: OR: 1.369, 1.193–1.570, p < 0.001; Daytime dysfunction: OR: 1.702, 1.278–2.267, p < 0.001) except the use of sleep drug subgroup were significantly positively correlated with LUTS/BPH prevalence. Significant interaction effects were observed in age subgroups (age-young group: age < 51; age-middle group: 51 ≤ age ≤ 61;
Benign prostatic hyperplasia (BPH) is the most common benign disease among the causes of micturition disorders in elderly men. It usually occurs after the age of 40. The prevalence rate of men over the age of 50 is 50%, and it is as high as 83% at the age of 80 (Berry et al., 1984; Gu et al., 1994). Wang et al. (2015) showed that the prevalence of BPH in Chinese population gradually increased from 2.9 to 69.2% among 40–80 years old. It is obvious that the prevalence of BPH has increased sharply with the age of Chinese men. The high prevalence of BPH greatly increases the health and economic burden of our society and the pain of these patients (Speakman et al., 2015).

Benign prostatic hyperplasia is due to the proliferation of stromal cells and epithelial cells stimulated by hormones and their active metabolites, causing the formation of anatomical hypertrophy prostate, which is manifested as urodynamic bladder outlet obstruction (BOO), resulting in lower urinary tract symptoms (LUTS), such as urinary retention, weak urine flow, etc. (Chughtai et al., 2016; Pejčić et al., 2017). In this study, LUTS/BPH refers to LUTS mainly manifested as obstruction caused by BPH.

Some studies have confirmed that sleep ensures the completion of important physiological functions by promoting the development of the central nervous system and the recovery of physical functions, which is a key factor in maintaining health (Tufik et al., 2009; Li et al., 2021). Researches involving both animals and humans have shown that sleep restriction can cause cognitive, immune, metabolic and hormonal disorders (Spiegel et al., 1999; Everson and Crowley, 2004; Hipólido et al., 2006). Previous cohort studies conducted by Koskderelioğlu et al. (2017) and Branche et al. (2018) showed that poor sleep quality was associated with prostate disease.

However, the correlation between sleep quality and the risk of LUTS/BPH in Chinese men remains uncertain. Therefore, the purpose of this study is to analyze the potential association between sleep quality (measured by PSQI score) and LUTS/BPH in Chinese men. Importantly, the results may support the discovery of new strategies to prevent LUTS/BPH and improve the quality of life of aging population.

### Materials and methods

#### Study population

The current research is a cross-sectional analysis based on the data of the West China Natural Population Cohort Study (WCNPCS) collected from May 2019 to June 2021. The sampling method of this study is cluster sequential sampling and the data was collected from three regions of Sichuan Province, the most populous province in Western China, including Mianzhu, Longquan, and Pidu. This study aimed to establish a large-scale prospective follow-up natural population cohort and collect various information of community participants in order to evaluate the health status of the general population in Western China.

A total of 36,075 participants aged 18–65 were included in this study. Participants were further excluded for lack of sleep quality and LUTS/BPH disease information (n = 1,102) and sleep quality score data (n = 23,149). Our final analysis sample was 11,824 participants (Figure 1). Specific general information (e.g., demographics, social-economic, education level and physical activities) was obtained through face-to-face interviews. Participants were further recruited for physical examination to collect biological samples, which were conducted by trained medical personnel in specially equipped mobile examination centers (MECs). Participants were recruited on a voluntary basis, and each participant signed and obtained informed consent before the survey. All research protocols were in accordance with the 1975 Helsinki Declaration and the applicable amendments at the time of the survey. The study protocol was approved by the ethics committee of West China.
Measurement of sleep quality

A PSQI questionnaire translated into Chinese was used to evaluate sleep quality. It is a standard self-report, including a 19-item questionnaire designed to collect a person’s subjective feelings about sleep habits for more than 1 month (Buysse et al., 1989). Each item is divided into four levels, with scores ranging from 0 to 3. PSQI has been used to diagnose sleep disorders in many clinical applications and has been proved to have good reliability, validity, and sensibility (Tsai et al., 2005; Mollayeva et al., 2016). It estimates several different aspects of sleep, which affect seven aspects of sleep problems, including subjective sleep quality, sleep latency, sleep duration, habitual sleep frequency, sleep disorders, use of sleep drugs, and daytime dysfunction (Buysse et al., 1989). The sum constitutes the global sleep quality score (ranging from 0 to 21), and the higher score means the worse sleep quality. The global PSQI score is divided by 7 points, which can distinguish poor or good sleep. It has high diagnostic sensitivity and specificity in Chinese population (98.3 and 90.2% respectively) (Li et al., 2021).

Measurement of lower urinary tract symptoms/benign prostatic hyperplasia

In addition, males were asked, “Have you ever been diagnosed with prostate hyperplasia?” Related symptoms of prostatic hyperplasia, including difficulty urinating, increased nocturia, urinary incontinence, were explained to all the participants. In WCNPCS study, symptoms were mainly assessed based on participant self-report, which was also commonly used in previous studies (Verhamme et al., 2002; Xiong et al., 2020; Zhang et al., 2022). The current study showed that men with sleep disorders are more likely to report daytime LUTS (Fantus et al., 2018). In order to make the results more reliable and exclude the direct impact of nocturia on sleep, We introduced daytime LUTS, which means symptoms of LUTS/BPH except nocturia.

Covariates

Information about sociodemographic characteristics and lifestyle factors was collected through questionnaire survey. For continuous covariates including age (year), body mass index (BMI, kg/m2), waist-to-hip ratio (WHR), the patient...
| Variable                        | Total       | Yes (n = 2,901)            | No (n = 8,923)            | P-value         |
|--------------------------------|-------------|---------------------------|---------------------------|----------------|
| **Age (year)**                 | 57.8 ± 12.40| 60.5 ± 11.81              | 56.9 ± 12.46              | <0.001         |
| **BMI (kg/m²)**                | 24.79 ± 3.21| 24.76 ± 3.17              | 24.80 ± 3.22              | 0.676          |
| **WHR**                        | 0.89 ± 0.06 | 0.89 ± 0.06               | 0.88 ± 0.06               | <0.001         |
| **PHQ-9**                      | 0.814 ± 2.00| 0.94 ± 2.19               | 0.78 ± 1.93               | <0.001         |
| **GAD-7**                      | 0.76 ± 2.09 | 0.85 ± 2.27               | 0.73 ± 2.03               | 0.003          |
| **Cr (µmol/L)**                | 72.62 ± 24.19| 71.91 ± 15.80             | 72.85 ± 26.35             | <0.001         |
| **Educational level**          |             |                           |                           |                |
| Primary school                 | 3,371 (34.16%)| 985 (41.65%)              | 2,386 (31.80%)            |                |
| Junior school                  | 3,785 (38.36%)| 912 (38.56%)              | 2,873 (38.29%)            |                |
| High school                    | 1,543 (15.64%)| 307 (12.98%)              | 1,236 (16.47%)            |                |
| College                        | 1,144 (11.59%)| 157 (6.64%)               | 987 (13.16%)              |                |
| Graduate                       | 25 (0.25%)  | 4 (0.17%)                 | 21 (0.28%)                |                |
| **Marital status**             |             |                           |                           | <0.001         |
| Married                        | 11,006 (93.83%)| 2,680 (93.32%)             | 8,326 (93.99%)            |                |
| Unmarried                      | 190 (1.62%) | 29 (1.01%)                | 161 (1.82%)               |                |
| Divorced                       | 209 (1.78%) | 54 (1.88%)                | 155 (1.75%)               |                |
| Widowed                        | 136 (1.16%) | 47 (1.64%)                | 89 (1.01%)                |                |
| **Smoking status**             |             |                           |                           | <0.001         |
| Current                        | 5,053 (42.79%)| 1,267 (43.68%)             | 3,786 (42.51%)            |                |
| Occasionally                   | 352 (2.98%) | 69 (2.38%)                | 283 (3.18%)               |                |
| Ever                           | 1,541 (13.05%)| 450 (15.51%)              | 1,091 (12.25%)            |                |
| Never                          | 4,862 (41.18%)| 1,115 (38.44%)             | 3,747 (42.07%)            |                |
| **Drinking status**            |             |                           |                           | 0.044          |
| Yes                            | 6,072 (51.43%)| 1,445 (49.83%)             | 4,627 (51.95%)            |                |
| Ever                           | 868 (7.35%) | 238 (8.21%)               | 630 (7.07%)               |                |
| No                             | 4,886 (41.22%)| 1,217 (41.97%)             | 3,649 (40.97%)            |                |
| **Coffee drinking**            |             |                           |                           | <0.001         |
| 1–2 times per week             | 752 (6.37%) | 141 (4.86%)               | 611 (6.86%)               |                |
| 3–5 times per week             | 75 (0.64%) | 10 (0.35%)                | 65 (0.73%)                |                |
| > 5 times per week             | 74 (0.63%) | 21 (0.72%)                | 53 (0.60%)                |                |
| No                             | 10,901 (92.37%)| 2,727 (94.07%)             | 8,174 (91.81%)            |                |
| **Tea drinking**               |             |                           |                           | <0.001         |
| 1–2 times per week             | 1,699 (14.40%)| 350 (12.07%)              | 1,349 (15.15%)            |                |
| 3–5 times per week             | 925 (7.84%) | 186 (6.42%)               | 739 (8.30%)               |                |
| > 5 times per week             | 5,147 (43.61%)| 1,320 (45.53%)             | 3,827 (42.99%)            |                |
| No                             | 4,031 (34.16%)| 1,043 (35.98%)             | 2,988 (33.56%)            |                |
| **Comorbidity index**          |             |                           |                           | <0.001         |
| 0                              | 5,737 (48.53%)| 1,256 (43.30%)             | 4,481 (50.24%)            |                |
| 1                              | 5,646 (47.76%)| 1,500 (51.71%)             | 4,146 (46.48%)            |                |
| 2                              | 422 (3.57%)  | 139 (4.79%)               | 283 (3.17%)               |                |
| 3                              | 16 (0.14%)  | 6 (0.21%)                 | 10 (0.11%)                |                |
| **DM**                         |             |                           |                           | 0.005          |
| Yes                            | 893 (7.58%) | 259 (8.97%)               | 634 (7.13%)               |                |
| Prediabetes                    | 147 (1.25%) | 36 (1.25%)                | 111 (1.25%)               |                |
| No                             | 10,739 (91.17%)| 2,594 (89.79%)             | 8,145 (91.62%)            |                |
| **Physical activity**          |             |                           |                           | <0.001         |
| Sufficient                     | 5,877 (49.77%)| 1,470 (50.67%)             | 4,407 (49.48%)            |                |
| Not sufficient                  | 1,550 (13.13%)| 303 (10.45%)              | 1,247 (14.00%)            |                |
| Inactive                       | 4,381 (37.10%)| 1,128 (38.88%)             | 3,253 (36.52%)            |                |

BMI, body mass index; WHR, waist-to-hip ratio; PHQ-9, the patient health questionnaire-9; GAD-7, generalized anxiety disorder-7; Cr, creatinine; DM, diabetes mellitus.
FIGURE 2
Comparison of the sleep quality between LUTS/BPH and non-LUTS/BPH groups.

TABLE 2
Associations between sleep disorder and LUTS/BPH and daytime LUTS/BPH.

|                      | Non-adjusted OR (95%CI) | P-value | Adjusted I OR (95%CI) | P-value | Adjusted II OR (95%CI) | P-value |
|----------------------|-------------------------|---------|-----------------------|---------|------------------------|---------|
|                      | N                       |         |                       |         |                        |         |
| LUTS/BPH             |                         |         |                       |         |                        |         |
| Sleep disorder       |                         |         |                       |         |                        |         |
| No                   | 1                       | 1       | 1                     | 1       |                        |         |
| Yes                  | 1.427 (1.298, 1.570)    | <0.001  | 1.372 (1.245, 1.512)  | <0.001  | 1.257 (1.119, 1.411)   | <0.001  |
| Global PSQI score    | 1.043 (1.029, 1.057)    | <0.001  | 1.037 (1.023, 1.051)  | <0.001  | 1.021 (1.004, 1.038)   | 0.013   |
| Daytime LUTS/BPH      |                         |         |                       |         |                        |         |
| Sleep disorder       |                         |         |                       |         |                        |         |
| No                   | 1                       | 1       | 1                     | 1       |                        |         |
| Yes                  | 1.605 (1.458, 1.767)    | <0.001  | 1.534 (1.390, 1.691)  | <0.001  | 1.343 (1.193, 1.512)   | <0.001  |
| Global PSQI score    | 1.072 (1.058, 1.086)    | <0.001  | 1.064 (1.050, 1.078)  | <0.001  | 1.044 (1.026, 1.061)   | <0.001  |

Non-adjusted: no covariates were adjusted.
Adjusted I: adjusted for age.
Adjusted II: adjusted for age, BMI, educational level, marital status, smoking status, drinking status, coffee intake, tea intake, WHR, PHQ-9, GAD-7, comorbidity index, DM, physical activity, Cr.

health questionnaire-9 (PHQ-9), generalized anxiety disorder-7 (GAD-7) and creatinine (Cr µmol/L). For categorical covariates including education level (primary school, junior school, high school college, or graduate), marital status (married, unmarried, divorced, or widowed), smoking status (current, occasionally, ever or never), drinking status (yes, ever or no), coffee and tea intake (1–2 times/week, 3–5 times/week or >5 times/week), comorbidity index, diabetes mellitus (DM) (yes, prediabetes or no) and physical activity (sufficient, not sufficient or inactive). Diabetes mellitus, congestive heart failure,
coronary artery disease, chronic obstructive pulmonary disease (chronic bronchitis and/or emphysema) and hypertension, cancer consisted of comorbid conditions. The number of subjects reported conditions were then combined to generate an ordinal comorbidity index. Exclusive diabetes was excluded and the total number of reported diseases was merged to create a sequential comorbidity index (Fantus et al., 2018). Individuals with a PHQ-9 score ≥ 10 are considered to have depressive symptoms (Kroenke et al., 2001). Calculate the average intake of coffee or tea in the dietary interview.

| TABLE 3 Regression analysis between PSQI components and LUTS/BPH regression analysis. |
|-----------------------------------------------|-------------------------------|----------------|-----------------------------|----------------|----------------|----------------|
|                                | Non-adjusted OR (95%CI) | P-value | Adjusted I OR (95%CI) | P-value | Adjusted II OR (95%CI) | P-value | P for trend |
| Subjective sleep quality          |                             |         |                             |         |                             |         |             |
| 0                                | 1.197 (1.072, 1.336)       | 0.001   | 1.163 (1.040, 1.300)       | 0.008   | 1.130 (0.995, 1.284)       | 0.060   | <0.001      |
| 1                                | 1.657 (1.440, 1.906)       | <0.001  | 1.635 (1.418, 1.886)       | <0.001  | 1.535 (1.299, 1.814)       | <0.001  |             |
| 2                                | 1.931 (1.494, 2.497)       | <0.001  | 1.800 (1.384, 2.342)       | <0.001  | 1.376 (1.004, 1.886)       | 0.048   |             |
| Sleep latency                    |                             |         |                             |         |                             |         | <0.001      |
| 0                                | 0.991 (0.887, 1.107)       | 0.872   | 1.000 (0.894, 1.118)       | 0.994   | 0.893 (0.783, 1.018)       | 0.089   |             |
| 1                                | 0.565 (0.507, 0.630)       | <0.001  | 0.603 (0.540, 0.673)       | <0.001  | 0.500 (0.439, 0.569)       | <0.001  |             |
| 2                                | 0.808 (0.705, 0.926)       | 0.002   | 0.833 (0.726, 0.957)       | 0.010   | 0.656 (0.557, 0.773)       | <0.001  |             |
| Sleep duration                   |                             |         |                             |         |                             |         | <0.001      |
| 0                                | 1.143 (1.037, 1.260)       | 0.007   | 1.137 (1.030, 1.255)       | 0.011   | 1.120 (0.999, 1.255)       | 0.052   |             |
| 1                                | 1.396 (1.214, 1.604)       | <0.001  | 1.276 (1.107, 1.470)       | 0.001   | 1.218 (1.035, 1.432)       | 0.017   |             |
| 2                                | 1.710 (1.454, 2.012)       | <0.001  | 1.537 (1.303, 1.814)       | <0.001  | 1.441 (1.189, 1.745)       | <0.001  |             |
| Habitual sleep efficiency         |                             |         |                             |         |                             |         | <0.001      |
| 0                                | 1.171 (1.049, 1.308)       | 0.005   | 1.099 (0.982, 1.230)       | 0.099   | 1.135 (0.999, 1.289)       | 0.051   |             |
| 1                                | 1.487 (1.307, 1.692)       | <0.001  | 1.362 (1.194, 1.554)       | <0.001  | 1.306 (1.123, 1.520)       | 0.001   |             |
| 2                                | 1.650 (1.471, 1.849)       | <0.001  | 1.451 (1.289, 1.632)       | <0.001  | 1.369 (1.193, 1.570)       | <0.001  |             |
| Sleep disturbance                |                             |         |                             |         |                             |         |             |
| 0                                | 1.217 (1.069, 1.384)       | 0.003   | 1.104 (0.967, 1.259)       | 0.143   | 1.022 (0.881, 1.184)       | 0.777   | 0.002       |
| 1                                | 1.898 (1.595, 2.259)       | <0.001  | 1.686 (1.411, 2.013)       | <0.001  | 1.354 (1.102, 1.664)       | 0.004   |             |
| 2                                | 3.022 (1.520, 6.011)       | 0.002   | 2.568 (1.283, 5.141)       | 0.008   | 2.539 (1.169, 5.518)       | 0.019   |             |
| Use of sleep drugs               |                             |         |                             |         |                             |         | 0.086       |
| 0                                | 1.252 (0.770, 2.035)       | 0.365   | 1.216 (0.745, 1.985)       | 0.435   | 1.152 (0.648, 2.050)       | 0.629   |             |

(Continued)
TABLE 3 (Continued)

|  | Non-adjusted OR (95%CI) | P-value | Adjusted I OR (95%CI) | P-value | Adjusted II OR (95%CI) | P-value | P for trend |
|---|--------------------------|---------|-----------------------|---------|------------------------|---------|------------|
| 2 | 1.477 (0.866, 2.520)    | 0.152   | 1.347 (0.784, 2.313)  | 0.281   | 1.149 (0.596, 2.218)   | 0.678   |            |
| 3 | 1.706 (1.113, 2.615)    | 0.014   | 1.497 (0.972, 2.366)  | 0.067   | 1.517 (0.927, 2.481)   | 0.097   |            |

Daytime dysfunction

|  | 0 | 1 | 1 | 1 |
|---|---|---|---|---|
| 2 | 1 | 1.970 (0.858, 1.097) | 0.631 | 1.111 (0.979, 1.260) | 0.103 | 1.084 (0.935, 1.256) | 0.286 |
| 3 | 1 | 1.033 (0.871, 1.226) | 0.710 | 1.196 (1.003, 1.425) | 0.046 | 1.152 (0.942, 1.408) | 0.168 |
| 3 | 1 | 1.603 (1.253, 2.050) | <0.001 | 1.890 (1.469, 2.431) | <0.001 | 1.702 (1.278, 2.267) | <0.001 |

Non-adjusted: no covariates were adjusted. Adjusted I: adjusted for age. Adjusted II: adjusted for age, BMI, educational level, marital status, smoking status, drinking status, coffee intake, tea intake, WHR, PHQ-9, GAD-7, comorbidity index, DM, physical activity, Cr.

in a week to indicate the intake of caffeine (times/week, classification).

**Statistical analysis**

In this study, continuous variables were presented as mean ± standard deviation, while categorical variables were presented as proportions. Chi-square (or Fisher's exact test) analysis was used to assess categorical variables and t-test analysis was used to assess continuous variables. Multivariate logistic regression analysis was used to examine the odds ratio (or) and 95% confidence interval (CI) of the risk of LUTS/BPH. The independent variable in this study is the presence or absence of LUTS/BPH status, and sleep quality (PSQI global score ≤ 7 or >7) and seven components of PSQI were used as independent variables. ORs and 95% CI were calculated. Meanwhile, we regard the PSQI global score as a continuous variable and conduct multiple logistic regression analysis as a sensitivity analysis. The ORs were adjusted for age in the minimum adjustment model (Model I). In the fully-adjusted model (Model II), the ORs is adjusted for age, BMI, educational level, marital status, smoking status, drinking status, coffee intake, tea intake, WHR, PHQ-9, GAD-7, comorbidity index, DM, physical activity and Cr. We repeated the above analysis in daytime LUTS to reduce the impact of nocturia on the results. In order to explore whether this association was modified by other confounding factors, we conducted subgroup analyses. The statistical software packages R¹ (The R Foundation) and EmpowerStats² (X&Y Solutions, Inc., Boston, MA, United States) were used in the above statistical analyses. A p-value < 0.05 was considered statistically significant.

**Results**

**Study population**

A total of 11,824 participants were included in the study. Table 1 details the baseline characteristics of participants. The LUTS/BPH group was older, with higher WHR, lower education level, higher anxiety index, more obvious depression, easier smoking, more tea intake, higher comorbidity index, and inactive outdoor sports. In addition, there were significant differences in creatinine concentration, marital status, drinking, and coffee intake in the group with LUTS/BPH (P < 0.005).

**Association between sleep quality and lower urinary tract symptoms/benign prostatic hyperplasia**

We compared the distribution of sleep quality between the two groups with and without LUTS/BPH (Figure 2). In the LUTS/BPH group with a global PSQI score higher than 7, and this group showed higher score, which means worse sleep quality in six aspects: objective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance and daytime dysfunction, which were more obvious than those without LUTS/BPH. Among them, the difference of habitual sleep efficiency between the two groups was the most obvious. The above results have significant statistical significance (P < 0.005).
In addition, it was found that sleep disorders were associated with an increased prevalence of LUTS/BPH. As a sensitivity analysis, we excluded daytime LUTS/BPH analysis after nocturia, similarly, sleep disorders were positively correlated with increased prevalence of daytime LUTS/BPH (Table 2), further enhancing the robustness of our study.

The results of logistic regression analyses of the correlation between global PSQI and its seven components and LUTS/BPH prevalence among participants were shown in Table 3. In the crude model, the global PSQI score (≤7 or >7) was positively correlated with the prevalence of LUTS/BPH. After adjusting for confounding variables, the global PSQI score (≤7 or >7) was still significantly positively correlated with the prevalence of LUTS/BPH (FOR: 1.201; 95% CI: 1.004–1.038; P = 0.013). Similar results can be observed in the seven components of PSQI. We found that among the six components other than use of sleep drugs, the higher PSQI components score, the more significant positive correlation between sleep quality and the risk of LUTS/BPH (P < 0.05).

Subgroup analysis stratified by the age of participants also found a positive correlation between sleep quality and the prevalence of LUTS/BPH (Table 4). We observed no statistically significant association of sleep quality and LUTS/BPH among young-aged male participants. On the other hand, among the middle and older-aged male participants, higher PSQI score (>7) were significantly associated with the increased prevalence of LUTS/BPH in all models (51 ≤ middle-aged ≤ 61: OR: 1.277; 95% CI: 1.026–1.589; P = 0.029) (older-aged > 61: OR: 1.277; 95% CI: 1.088–1.499; P = 0.003) (Figure 3). Meanwhile, we observed a significant interaction between sleep quality and LUTS/BPH in the correlation of age in the three models (P for interaction = 0.005). In addition, we further carried out subgroup analysis (Figure 4). The results of subgroup analysis showed that our findings were significant in most subgroups (P < 0.05), reflecting the stability of the results. Only in the age < 52 group and BMI > 28 group, we did not observe significant results.
FIGURE 3
Smooth curve fitting of sleep disorder and risk of LUTS/BPH, grouped by age.

FIGURE 4
Subgroup analysis by age, BMI, smoking, drinking status on association between PSQI with LUTS/BPH.
Discussion

With the continuous development of population aging trend, it is estimated that by 2050, the population over 65 years old will reach 400 million (accounting for 26.9% of the total population), and the population over 80 years old can grow to 150 million (Fang et al., 2015). More evidence shows that LUTS/BPH is the manifestation of urinary system caused by multiple systems (Fantus et al., 2018). The purpose of this study was to further clarify the correlation between sleep disorders and LUTS/BPH in Chinese males. The data come from a large natural population cohort represented by people in Southwest China. This study showed that poor sleep quality was significantly associated with the prevalence of LUTS/BPH in men. In the subgroup analysis, the fully adjusted model results showed that the significant association between poor sleep quality and the prevalence of LUTS/BPH mainly existed in men aged ≥ 51. There was a significant interaction between age and sleep quality and the prevalence of LUTS/BPH.

The results of a prospective cohort study conducted by Araujo et al. (2014) showed that the correlation between sleep disorders and urinary symptoms is bi-directional. Similar results were also observed in the study of Scovell et al. (2017), which also found that men with sleep difficulties, difficulty in maintaining sleep and difficulty in returning to sleep reported more serious LUTS than men without similar sleep difficulties. The results of the above articles show that sleep problems are associated to male LUTS/BPH, which is consistent with the results of this study.

There are several hypotheses about the biological basis of sleep and its correlation with LUTS/BPH. One theory involves the role of circadian rhythm in hormone metabolism. Sleep structure is usually affected by the aging process: it becomes more and more fragmented due to the arousals and episodes of awakening, which may lead to poor sleep maintenance and consolidation, as well as the reduction of the overall amount of sleep (Kryger et al., 2004). Now emerging evidence shows that similar partial sleep deprivation patterns can affect many aspects of mammalian endocrine system, including the decline of some anabolic hormones (Everson and Crowley, 2004). Age related sleep fragmentation may disrupt androgen secretion in older men (Luboshitzky et al., 2001). Copinschi and Caufriez (2013) found that circadian rhythm of circulating testosterone seems to be mainly driven by the sleep wake cycle. In fact, daytime and nighttime sleep are associated with strong increases in circulating testosterone levels. However, although it is weakened compared with night sleep, testosterone levels continue to rise when awake at night. Nocturnal sleep time has been shown to be an independent predictor of morning total and free testosterone in the elderly. Therefore, with the duration and length of sleep time, it has a great impact on the fluctuation of hormone level in the body, especially testosterone, so LUTS/BPH dependent on androgen level is more likely to occur. Related studies put forward a possibility that the change of sleep may be one of the mechanisms that transform the physiological aging process of the elderly into the change of neuroendocrine function (Penev, 2007). In addition, reduced sleep duration can cause the disorders of circadian clock genes, such as Per 2, Per 3 (Goel et al., 2013). Meanwhile, in the research results reported by Li et al. (2019), the decreased expression of Per 2 can inhibit cell apoptosis, leading to BPH. Therefore, good sleep is of great significance to maintain the stability of the circadian rhythm.

Another theory suggested that autonomic nerve activity may be one of the causes of LUTS/BPH in men. Roehrborn (2008) found that autonomic nervous system activity, plasma and urinary catecholamines were positively correlated with symptom scores and other BPH measurements. Meanwhile, previous studies by Spiegel et al. (1999) showed that the activity of sympathetic nervous system increased under the condition of sleep debt (p < 0.02). Thus, sleep disorder may affect the pathological changes of prostate by promoting the activity of sympathetic nerve, so as to cause the occurrence of LUTS. In addition, the latest research results suggested that prostatic hyperplasia and pathological progression are related to the level of inflammation, and sleep disorders can increase the level of inflammatory factors in the body (Navaneethakannan et al., 2022).

Subgroup analysis showed that the association between increased sleep disorder incidence and increased prevalence of LUTS/BPH was much more common among older male participants. Poor sleep has many negative effects on quality of life and increases the risk of other comorbidity such as depression, obesity, type 2 diabetes, cardiovascular disease, which may have a negative impact on mood, subjective well-being and overall function (Araujo et al., 2014; Scovell et al., 2017). For the elderly, the risk of comorbidity caused by sleep disorders will increase, which is more likely to lead to the occurrence of LUTS/BPH.

It should be noted that there are several limitations of this study. First, due to the cross-sectional nature of this study, the causal association between sleep quality and LUTS/BPH may not be clarified, and further prospective and intervention studies may provide a better explanation. Secondly, although we adjusted for potential confounding factors, we still can not rule out the impact of other unmeasured correlation factors on the results. What is more, because the diagnostic information of LUTS/BPH is self-reported, there is a risk of bias. Finally, there may be recall bias for some variables (such as smoking, drinking, exercise variables, etc.).

Conclusion

Our findings suggested that sleep disorders are associated with an increased prevalence of LUTS/BPH. Moreover, the significant interaction between age and sleep disorders showed
that older people are more likely to develop LUTS/BPH due to sleep disorders. Our study provides data support for the possible future proposal to prevent LUTS/BPH by improving sleep disorders. Their potential biological mechanisms need to be further studied.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Biomedical Ethics Review Committee of West China Hospital of Sichuan University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

YL contributed to the design of the study, was responsible for data processing and analysis, and drafted the initial manuscript. SQ, XZ, and KJ decided the methods of data analysis. LC, ZJ, DH, and MW were responsible for determining whether the data should be included in the discharge criteria. SW and BC polished the manuscript. QW, LY, and LM conceptualized and designed the study, supervised all aspects of the study, critically reviewed and revised the manuscript, and approved the final manuscript submitted. All authors read and approved the final manuscript.

Funding

This program was supported by the National Natural Science Foundation of China (Grant Nos. 81974099, 82170785, 81974098, and 82170784), programs from Science and Technology Department of Sichuan Province (Grant No. 21GJHZ0246), Young Investigator Award of Sichuan University 2017 (Grant No. 2017SCU04A17), Technology Innovation Research and Development Project of Chengdu Science and Technology Bureau (2019-YF05-00296-SN), and Sichuan University-Panzhihua Science and Technology Cooperation Special Fund (2020CDPZH-4).

Acknowledgments

The authors thank West China Hospital for conducting the survey and all participants for providing these data.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Araujo, A. B., Yaggi, H. K., Yang, M., McVary, K. T., Fang, S. C., and Bliwise, D. L. (2014). Sleep related problems and urological symptoms: Testing the hypothesis of bidirectionality in a longitudinal, population based study. J. Urol. 191, 100–106. doi: 10.1016/j.juro.2013.07.011

Berry, S. J., Coffey, D. S., Walsh, P. C., and Ewing, L. L. (1984). The development of human benign prostatic hyperplasia with age. J. Urol. 132, 474–479. doi: 10.1016/s0022-5347(17)49698-4

Branche, B. L., Howard, L. E., Moreira, D. M., Roehrborn, C., Castro-Santamaria, R., Andriole, G. L., et al. (2018). Sleep problems are associated with development and progression of lower urinary tract symptoms: Results from REDUCE. J. Urol. 199, 536–542. doi: 10.1016/j.juro.2017.08.108

Buysse, D. J., Reynolds, C. F. III, Monk, T. H., Berman, S. R., and Kupfer, D. J. (1989). The pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res. 28, 193–213. doi: 10.1016/0165-1781(89)90047-4

Chughtai, B., Forde, J. C., Thomas, D. D., Lao, L., Hossack, T., Woo, H. H., et al. (2016). Benign prostatic hyperplasia. Nat. Rev. Dis. Primers. 2:16031. doi: 10.1038/nrdp.2016.31

Copinschi, G., and Caufriez, A. (2013). Sleep and hormonal changes in aging. Endocrinol. Metab. Clin. North Am. 42, 371–389. doi: 10.1016/j.ecl.2013.02.009

Everson, C. A., and Crowley, W. R. (2004). Reductions in circulating anabolic hormones induced by sustained sleep deprivation in rats. Am. J. Physiol. Endocrinol. Metab. 286, E1060–E1070. doi: 10.1152/ajpendo.00553.2003

Fang, E. F., Scheibye-Knudsen, M., Jahn, H. J., Li, J., Ling, L., Guo, H., et al. (2015). A research agenda for aging in China in the 21st century. Ageing Res. Rev. 24, 197–205. doi: 10.1016/j.arr.2015.08.003

Fantus, R. J., Packiam, V. T., Wang, C. H., Erickson, B. A., and Helfand, B. T. (2018). The relationship between sleep disorders and lower urinary tract symptoms: Results from the NHANES. J. Urol. 200, 161–166. doi: 10.1016/j.juro.2018.01.083
Goel, N., Basner, M., Rao, H., and Dingel, D. F. (2013). Circadian rhythms, sleep deprivation, and human performance. Prog. Mol. Biol. Transl. Sci. 119, 155–190. doi: 10.1016/B978-0-12-396971-2.00007-5

Gu, F. L., Xia, T. L., and Kong, X. T. (1994). Preliminary study of the association between sleep and lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 44, 688–691. doi: 10.1016/s0090-4295(94)80207-6

Hipólito, D. C., Suchecki, D., Pimentel de Carvalho Pinto, A., Chiocchetti, A., Tufik, S., and Lux, J. (2006). Paradoxical sleep deprivation and sleep recovery: Effects on the hypothalamic-pituitary-adrenal axis activity, energy balance and body composition of rats. J. Neuroendocrinol. 18, 231–238. doi: 10.1111/j.1365-2826.2006.01412.x

Koskikorpi, A., Gedizlioglu, M., Ceylan, Y., Gunes, M., and Kahyaoglu, N. (2017). Quality of sleep in patients receiving androgen deprivation therapy for prostate cancer. NeuroL. Sci. 38, 1445–1451. doi: 10.1007/s10072-017-2989-3

Kroenke, K., Spitzer, R. L., and Williams, J. B. (2011). The PHQ-9: Validity of a brief depression severity measure. J. Gen. Intern. Med. 16, 606–613. doi: 10.1046/j.1525-1497.2001.016009606.x

Kryger, M., Monjan, A., Bliwise, D., and Ancoli-Israel, S. (2004). Sleep, health, and aging. Bridging the gap between science and clinical practice. Geriatrics 58, 24–26.

Li, B., Liu, N., Guo, D., Li, B., Li, B., and Liu, Y. (2021). Association between sleep quality and central obesity among southern Chinese reproductive-aged women. BMC Women Health 21:280. doi: 10.1186/s12905-021-01407-0

Li, Y., Shi, B., Dong, F., Zhu, X., Liu, B., and Liu, Y. (2019). Effects of inflammatory responses, apoptosis, and STAT3/NF-κB-mediated oxidative stress on benign prostatic hyperplasia induced by a high-fat diet. Aging 11, 5570–5578. doi: 10.18632/aging.102138

Lubosibtzyk, R., Zahari, Z., Shen-Orr, Z., Herer, P., and Lavi, P. (2001). Disruption of the nocturnal testosterone rhythm by sleep fragmentation in normal aged men. J. Clin. Endocrinol. Metab. 86, 1134–1139. doi: 10.1210/jcem.86.3.7296

Mollayeva, T., Thurairajah, P., Burton, K., Mollayeva, S., Shapiro, C. M., and Colantonio, A. (2016). The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. Sleep Med. Rev. 25, 52–73. doi: 10.1016/j.smrv.2015.01.009

Navaneethakannan, M., Nandeesha, H., and Sreenivasan, S. K. (2022). Relationship of interleukin-23 with matrix metalloproteinase-9, pentraxin-3, sleep quality and prostate size in benign prostatic hyperplasia. Andrologia 54:e14387. doi: 10.1111/and.14387

Pejić, T., Tosti, T., Telšić, Z., Milковић, B., Dragčević, D., Kozomara, M., et al. (2017). Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume. Prostate 77, 1082–1092. doi: 10.1002/pros.23365

Penev, P. D. (2007). Association between sleep and morning testosterone levels in older men. Sleep 30, 427–432. doi: 10.1093/sleep/30.4.427

Roehrborn, C. G. (2008). Pathology of benign prostatic hyperplasia. Int. J. Impot. Res. 20, S11–S18. doi: 10.1086/ijir.2008.55

Scovell, J. M., Pastuszak, A. W., Slawin, J., Badal, J., Link, R. E., and Lipsultz, L. I. (2017). Impaired sleep quality is associated with more significant lower urinary tract symptoms in male shift workers. Urology 99, 197–202. doi: 10.1016/j.urology.2016.05.076

Speakman, M., Kirby, R., Doyle, S., and Ioannou, C. (2015). Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 115, 508–519. doi: 10.1111/bju.12745

Speigel, K., Leproult, R., and Van Cauter, E. (1999). Impact of sleep debt on metabolic and endocrine function. Lancet 354, 1435–1439. doi: 10.1016/S0140-6736(99)01376-8

Tsai, P. S., Wang, S. Y., Wang, M. Y., Su, C. T., Yang, T. T., Huang, C. J., et al. (2005). Psychometric evaluation of the Chinese version of the Pittsburgh sleep quality index (CPSQI) in primary insomnia and control subjects. Qual. Life Res. 25, 52–73. doi: 10.1007/s11136-005-4346-x

Tufik, S., Anderssen, M. L., Bittencourt, L. R., and Mello, M. T. (2009). Paradoxical sleep deprivation: Neurochemical, hormonal and behavioral alterations. Evidence from 30 years of research. An. Acad. Bras. Cienc. 81, 521–538. doi: 10.1590/S0001-47022009000300016

Verhamme, K. M., Duleman, J. P., Bleumink, G. S., van der Lei, J., Sturkenboom, M. C., Arribiani, W., et al. (2002). Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care–the Triumph project. Eur. Urol. 42, 323–328. doi: 10.1016/S0148-2941(02)00354-8

Wang, W., Guo, Y., Zhang, D., Tian, Y., and Zhang, X. (2015). The prevalence of benign prostatic hyperplasia in mainland China: Evidence from epidemiological surveys. Sci. Rep. 5:13546. doi: 10.1038/srep13546

Xiong, Y., Zhang, Y., Xu, L., Qiu, F., and Yuan, J. (2020). The prevalence and associated factors of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males. Aging Male 23, 1432–1439. doi: 10.1080/13688358.2020.1781806

Zhang, W., Cao, G., Sun, Y., Wu, F., Wang, Q., Xu, T., et al. (2022). Depressive symptoms in individuals diagnosed with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in middle-aged and older Chinese individuals: Results from the China health and retirement longitudinal study. J. Affect. Disord. 296, 660–666. doi: 10.1016/j.jad.2021.09.045